BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 964 filers reported holding BAXTER INTL INC in Q2 2017. The put-call ratio across all filers is 0.35 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $93,967,000 | +9.5% | 1,552,146 | -6.2% | 0.31% | +2.6% |
| Q1 2017 | $85,831,000 | +26.3% | 1,655,046 | +8.0% | 0.30% | +17.3% |
| Q4 2016 | $67,977,000 | +12.5% | 1,533,099 | +20.8% | 0.26% | +20.4% |
| Q3 2016 | $60,412,000 | +21.8% | 1,269,163 | +15.7% | 0.22% | +18.0% |
| Q2 2016 | $49,602,000 | +9.3% | 1,096,918 | -0.7% | 0.18% | +10.9% |
| Q1 2016 | $45,374,000 | -84.5% | 1,104,544 | -86.8% | 0.16% | -83.4% |
| Q4 2015 | $292,527,000 | -11.0% | 8,377,024 | -16.2% | 1.00% | -11.3% |
| Q3 2015 | $328,568,000 | -57.8% | 10,002,063 | -10.2% | 1.12% | -50.0% |
| Q2 2015 | $779,203,000 | -6.9% | 11,143,661 | -8.8% | 2.24% | -0.4% |
| Q1 2015 | $837,116,000 | -13.3% | 12,220,669 | -7.2% | 2.25% | -7.1% |
| Q4 2014 | $965,462,000 | -0.4% | 13,173,179 | -2.4% | 2.42% | +13.3% |
| Q3 2014 | $969,043,000 | +1.9% | 13,502,069 | +2.6% | 2.14% | +7.9% |
| Q2 2014 | $951,062,000 | -8.5% | 13,154,382 | -7.0% | 1.98% | -31.7% |
| Q1 2014 | $1,039,851,000 | -0.3% | 14,151,266 | -5.9% | 2.90% | -0.4% |
| Q4 2013 | $1,042,908,000 | +46.4% | 15,038,086 | +38.9% | 2.92% | +45.4% |
| Q3 2013 | $712,356,000 | +35.9% | 10,828,679 | +43.1% | 2.00% | +20.1% |
| Q2 2013 | $524,139,000 | – | 7,566,462 | – | 1.67% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |